The Week

Alaunos Therapeutics (TCRT) lost 9.17% this week to close at $1.09, while the S&P 500 gained 1.21%, leaving the stock roughly 10.38 percentage points behind the benchmark. It was a pullback after an early pop: the stock opened Monday at $1.26 and touched $1.35 intraday, held near $1.27 on Tuesday, then drifted lower each day to finish at $1.09 on Friday, the low end of the week. Weekly amplitude was 21.43%.

Key Events

The week’s main development landed on Wednesday, when Alaunos announced a securities purchase agreement with accredited investors and a new registered direct offering. Monday’s pre-market note had already flagged financing and charter amendments, and the company filed a 424B3 on Tuesday to lay the groundwork. Intraday moves were choppy: the stock rose 5.00% in overnight trading Monday, fell 3.33% pre-market the same day, then slipped another 3.17% overnight Tuesday, suggesting the market digested the financing news with some hesitation.

Analyst Ratings

One covering broker currently rates the stock hold, with a consensus rating of hold. The consensus target price is $205.4999, which sits about 18,753.20% above the current price of $1.09. With only one rating in the set, there is no dispersion to read. The rating data was last updated on 15 February 2024, and industry ranking data is not disclosed.

The Week Ahead

Next week brings a run of US macro readings: the Dallas Fed manufacturing business activity index on Monday, followed on Tuesday by FHFA house prices, the Case Shiller 20-city home price index, JOLTS job openings and consumer confidence. For Alaunos, the near-term watch is the pace of funding after this week’s securities purchase agreement and registered direct offering, and how the stock responds to the dilution story.

In Short

The tension this week: Alaunos pushed ahead with financing and charter changes, yet the stock faded after an early surge and closed the week down 9.17%. The price-to-book ratio is about 4.25x, and the latest session’s flow shows small and medium orders roughly balanced, with no large-order direction. The next question is how the registered direct offering plays out and whether prices can hold above the week’s low.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.